Dr. Daniel Refai, MD

Dr. Refai practices at Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University.

Dr. Refai's NPI, 1912092800, was assigned on October 4, 2006. Dr. Refai graduated from University of Chicago, Pritzker School of Medicine in 2003. Dr. Refai holds Georgia license 64254.

Dr. Refai's primary practice is Emory University Hospital Midtown, at 550 Peachtree Street, NE, Atlanta, GA 30308 in Fulton County. The practice phone is (404) 686-2450.

Dr. Refai's primary practice is Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University. Dr. Refai is also affiliated with Emory University Hospital. The medical group on file is Emory Clinic. Dmand AI also links Dr. Refai to 3 more hospitals, 4 group practices and clinics, 3 medical groups and 1 clinical lab, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Refai practices, 10 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Refai's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dmand AI has Dr. Refai's licenses on file in 4 states: Georgia, California, Missouri and Ohio.

CMS data shows 435 Medicare services from Dr. Refai across 8 procedure codes in 2024, for 247 Medicare patients. Medicare paid $74,474 for them.

CMS counts 247 Medicare patients who saw Dr. Refai in 2024. The largest group is 65 to 74, with 122 patients. 75% of them have arthritis, and 75% have high blood pressure. 14% are also on Medicaid. Their average risk score is 1.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Refai's median patient age at 68, with 54% women.

In 2024, Dr. Refai wrote 359 Medicare Part D claims for 141 patients. 98% of them were for generic drugs. CMS names the drug for 281 of them, across 10 drugs with 11 or more claims each, at $2,340 in total drug cost. In 2023, CMS named 314 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Refai for performance year 2024, reported through an alternative payment model (APM). Dr. Refai accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Refai as offering telehealth. CMS counts 91 procedures of laminectomy or laminotomy (partial removal of spine bones) by Dr. Refai, more than 92% of the clinicians it reports for that procedure.

Dmand AI links 27 papers to Dr. Refai, published from 2011 to 2025. 2016 was the busiest year, with 3. The most frequent topics are Spinal Fusion, Cervical Vertebrae and Postoperative Complications. Dr. Refai has published most often in Neurosurgery. Dr. Refai's most frequent co-authors are Matthew Frank Gary, MD, Gerald E. Rodts, MD and Geoffrey Paul Stricsek, MD.

Dmand AI links Dr. Refai to 1 clinical trial. 1 is still active or recruiting.

CMS Open Payments shows 1,082 general payments to Dr. Refai from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. Stryker Corporation paid the most, $1,081,107.

Dr. Refai graduated from University of Chicago, Pritzker School of Medicine in 2003.